GlassScriptPhysician profile
Solange Sierra
NPI 1427525575
$11,837.59
in general payments reported to CMS, 2019-2025
15 companies · $8,535 in 2025
The $8,535 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,485 · 2022: $485 · 2023: $365 · 2024: $968 · 2025: $8,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,881 · Travel and Lodging: $2,139 · Consulting Fee: $2,115 · Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,881.25 |
| Travel and Lodging | $2,138.63 |
| Consulting Fee | $2,115.00 |
| Food and Beverage | $1,732.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $6,022.88 | 2021-2025 | Romvimza |
| Daiichi Sankyo INC. | $1,294.26 | 2022-2025 | Turalio |
| Ares Trading Sa | $1,134.83 | 2025 | |
| Aadi Bioscience, INC. | $1,104.00 | 2023-2025 | Fyarro |
| Emd Serono, INC. | $1,040.00 | 2025 | |
| Springworks Therapeutics, INC. | $301.88 | 2024-2025 | Ogsiveo, Gomekli |
| Astrazeneca Pharmaceuticals LP | $248.45 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $245.83 | 2021-2022 | |
| Exelixis INC. | $134.94 | 2021 | |
| Glaxosmithkline, LLC. | $113.40 | 2021 | |
| Foundation Medicine, INC. | $107.79 | 2021 | |
| Caris Mpi, INC. | $30.94 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $23.34 | 2023 | Tecvayli, Darzalex |
| Gilead Sciences, INC. | $19.16 | 2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solange Sierra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.